Jump to Navigation
MDA | Muscular Dystrophy Association
  • About MDA
  • Advocacy
  • Publications
  • Media
Give Now.
Give online Give by mail Give by phone

Main menu

  • Home
  • Learn About Muscle Diseases
  • Help Through Services
  • Hope Through Research
  • Ways to Help MDA

Search form

ALS, IBM — Eric Ross, Ph.D.

Eric Ross, Ph.D.
Yeast makes a powerful model system in which to study the spread of prion-like proteins, Ross says, because it grows rapidly and its genes can be easily manipulated. “Based on studies in yeast, our lab has developed methods to identify new disease-associated proteins in other organisms.”
Inclusion-Body Myositis (IBM)
Amyotrophic Lateral Sclerosis (ALS)

Eric Ross, associate professor of biochemistry and molecular biology at Colorado State University in Fort Collins, was awarded an MDA research grant totaling $363,000 over a period of three years to study proteins whose aggregation causes neurodegeneration.

Neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), are characterized by the formation of protein clumps, or aggregates, in or around muscle-controlling nerve cells called motor neurons. Aggregates also are seen in the muscle disease inclusion-body myositis (IBM). These aggregates are believed to indicate an ongoing toxic process within the cell and may be toxic themselves.

“Interestingly, similar protein aggregation can be seen even in simple single-cell organisms such as yeast,” says Ross. Some aggregates can harm not only the cell in which they form, but also neighboring cells by spreading to them and inducing aggregation. Such proteins are called prion-like for their resemblance to proteins found in prion diseases like bovine spongiform encephalopathy (mad cow disease).

Yeast makes a powerful model system in which to study the spread of prion-like proteins, Ross says, because it grows rapidly and its genes can be easily manipulated. “Based on studies in yeast, our lab has developed methods to identify new disease-associated proteins in other organisms. Remarkably, in just the past few years, various labs have linked mutations in six of these proteins to certain inclusion-body myopathies and some forms of ALS.”

Ross will be examining how the sequence of amino acids in these proteins affects aggregation and toxicity, and how disease-associated mutations change the physical properties of the proteins.

“These studies will provide insight into the causes of these diseases, facilitate the identification of potential drug targets for therapeutic intervention, and improve our ability to identify other disease-associated prion-like proteins,” he says.

Funding for this MDA grant began Feb. 1, 2013.

‹ ALS, IBM — Benoit Coulombe, Ph.D. up ALS, IBM — Hong Joo Kim, Ph.D. ›

Research

  • Research News
  • Active Research Grants
  • Research Grants Programs
  • MDA Translational Research Program
    • Clinical Research Training Grant (CRTG)
    • Funded Projects
    • MDA Venture Philanthropy
  • Opportunities for Researchers
  • Annual Conference Series
  • Grants at a Glance — Winter 2013
  • MDA Research Contact
  • Helpful Links
  • Clinical Trials and Studies
  • Newborn Screening for Neuromuscular Diseases
  • MyoBlast Research Newsletter
    • Volume 1, Issue 1, October 2011
    • Volume 2, Issue 1, February 2012

Grants at a Glance — Winter 2013

  • ALS — Daniela Zarnescu, Ph.D.
  • ALS — Fenghua Hu, Ph.D.
  • ALS — Giovanni Manfredi, M.D., Ph.D.
  • ALS — Heather Durham, Ph.D.
  • ALS — Jeffrey Rothstein, M.D., Ph.D.
  • ALS — Li Niu, Ph.D.
  • ALS — Mohamed Farah, Ph.D.
  • ALS — Sunitha Rangaraju, Ph.D.
  • ALS — Xin Wang, Ph.D.
  • ALS, CMT — Martha Bhattacharya, Ph.D.
  • ALS, IBM — Benoit Coulombe, Ph.D.
  • ALS, IBM — Eric Ross, Ph.D.
  • ALS, IBM — Hong Joo Kim, Ph.D.
  • BMD, DMD — Linda Baum, M.D., Ph.D.
  • CMD, LGMD — Sebahattin Cirak, M.D.
  • CMS — Michael Linhoff, Ph.D.
  • CMT — Ronald K. Liem, Ph.D.
  • CMT — Vera Fridman, M.D.
  • DM — Matthew Disney, Ph.D.
  • DMD — Deok-Ho Kim, Ph.D.
  • DMD — Eric Hoffman, Ph.D.
  • DMD — Gordon Lynch, Ph.D.
  • DMD — Joan Taylor, Ph.D.
  • DMD — Kay Davies, M.A., Ph.D.
  • DMD — Madhuri Hegde, Ph.D.
  • DMD — Matthew Alexander, Ph.D.
  • DMD, BMD — Joseph Beavo, Ph.D.
  • DMD, General MD — Radbod Darabi, M.D., Ph.D.
  • FA — Marek Napierala, Ph.D.
  • FA — Mark Payne, M.D.
  • FSHD — Michael Kyba, Ph.D.
  • FSHD — Rabi Tawil, M.D.
  • LGMD — Noah Weisleder, Ph.D.
  • Laing Distal Myopathy — Leslie Leinwand, Ph.D.
  • MG — David Richman, M.D.
  • MG — Muthusamy Thiruppathi, Ph.D.
  • MG — Socrates Tzartos, Ph.D.
  • MMD — Darren Monckton, Ph.D.
  • Mitochondrial Myopathies — Eric Schon, Ph.D.
  • Muscle Physiology — Masahiro Iwamoto, Ph.D., D.D.S.
  • OPMD — Ayan Banerjee, Ph.D.
  • OPMD — Sarah Youssof, M.D.
  • SMA — Christine DiDonato, Ph.D.
  • SMA — Gary Bassell, Ph.D.
  • SMA — John Manfredi, Ph.D.
MDA in Your Community

Quick Links

  • Tell Us About Your MDA Clinic
  • Become an MDA Advocate
  • Be a Summer Camp Volunteer
  • Sign Up for MDA News Updates
  • MDA's Muscle Shop

Give Now.

Ways To Help

  • Advocacy
  • Become a Volunteer
  • Donor Login
  • Legacy Gifts
  • MDA Programs
  • Matching Gifts

About MDA

  • Art Collection
  • Contact MDA
  • Become a Volunteer
  • Careers
  • FAQ
  • Media
  • What is MDA?

MDA.org

  • Find Support
  • Get Involved
  • Publications
  • Site Map
  • Muscle Shop

Connect with MDA

  • Facebook Twitter YouTube  

Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717

Privacy Policy | Terms of Use

©2013, Muscular Dystrophy Association Inc. All rights reserved.
 

Advertise